Human milk oligosaccharides (HMOs) are complex sugars found in breastmilk that support the growth of beneficial gut bacteria in infants and provide protection against pathogenic bacteria. As the third most abundant solid component in breastmilk after lactose and fat, HMOs mimic components of the mucosal layer in the infant gut and prevent pathogens from attaching to and colonizing the intestinal wall. Research has shown that HMOs can promote brain development and stimulate immune cell development in infants. Due to their demonstrated prebiotic and nutritional properties similar to human breastmilk, HMOs are being incorporated into infant formula to deliver health benefits to bottle-fed babies.
The global human milk oligosaccharides market is driven by growing awareness about the importance of HMOs in infant nutrition and development. As many mothers face difficulties in breastfeeding, the demand for HMO-fortified infant formula is increasing significantly. Major market players have developed technological capabilities to produce HMOs through the fermentation of various dairy and plant-based ingredients. However, the high costs involved in the production process pose a challenge to market growth. Ongoing research focused on reducing production costs could open up opportunities for the wider application of HMOs beyond infant nutrition in areas such as clinical nutrition, personal care, and supplemental food & beverages.
- This report provides in-depth analysis of the global human milk oligosaccharides market, and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2025–2032), considering 2024 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global human milk oligosaccharides market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies
- Key companies covered as a part of this study include ZuChem Inc., Merck & Co. Inc., Chr. Hansen Holding AS , Royal FrieslandCampina NV, BASF, IFF (DuPont Nutrition & Health), Gnubiotics, Inbiose NV, Carbosynth Holdings Limited, Royal DSM N.V, Kyowa Hakko Europe GmbH, Elicityl SA, FrieslandCampina Ingredients, Glycom A/S, Dextra Laboratories Limited, and Rajvi Enterprise
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- The global human milk oligosaccharides market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global human milk oligosaccharides market
- Infant Formula
- Dietary Supplements
- Functional Food and Beverage
- 2’FL
- 3’FL
- 3’SL
- 6’SL
- LNT
- LNnT
- North America
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East & Africa
- GCC Countries
- Israel
- Rest of Middle East & Africa
- ZuChem Inc.
- Merck & Co. Inc.
- Chr. Hansen Holding AS
- Royal FrieslandCampina NV
- BASF
- IFF (DuPont Nutrition & Health)
- Gnubiotics
- Inbiose NV
- Carbosynth Holdings Limited
- Royal DSM N.V
- Kyowa Hakko Europe GmbH
- Elicityl SA
- FrieslandCampina Ingredients
- Glycom A/S
- Dextra Laboratories Limited
- Rajvi Enterprise
